share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q：2024财年一季报
美股SEC公告 ·  2024/05/15 04:10

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmaceuticals公司（Conduit）报告了截至2024年3月31日的财务业绩。公司净亏损360万美元，与去年同期170万美元的净亏损相比有所增加。研发费用为128,000美元，用于开发针对自身免疫性疾病的AZD1656共晶的化合物。一般管理费用增长了87％至280万美元，主要是由于更高的薪水和股票补偿费用以及保险相关成本。其他收入和费用导致净费用为597,000美元，主要是由于授予认股权所致。利息支出为119,000美元。Conduit的经营活动现金流为净使用240万美元。公司未进行投资活动，并且该季度没有筹资活动的现金流量。Conduit的管理层正在寻求额外的资金来资助运营并继续作为一个运营单位。公司的未来计划包括推进临床资产的开发，并寻求授权机会的合作伙伴。
Conduit Pharmaceuticals公司（Conduit）报告了截至2024年3月31日的财务业绩。公司净亏损360万美元，与去年同期170万美元的净亏损相比有所增加。研发费用为128,000美元，用于开发针对自身免疫性疾病的AZD1656共晶的化合物。一般管理费用增长了87％至280万美元，主要是由于更高的薪水和股票补偿费用以及保险相关成本。其他收入和费用导致净费用为597,000美元，主要是由于授予认股权所致。利息支出为119,000美元。Conduit的经营活动现金流为净使用240万美元。公司未进行投资活动，并且该季度没有筹资活动的现金流量。Conduit的管理层正在寻求额外的资金来资助运营并继续作为一个运营单位。公司的未来计划包括推进临床资产的开发，并寻求授权机会的合作伙伴。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间